Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Globe Newswire•21/10/2026•08:30 ET
0
Key Highlights
- ➤31.2% achieved four-week sustained abstinence during treatment Weeks 49–52
- ➤39.4% of prior-placebo participants quit by Weeks 49–52
- ➤32.8% of exclusive smokers quit versus 24.6% of exclusive vapers
- ➤69.7% completed the 52-week study; 3.6% discontinued for treatment-related adverse events
Expert Statements
Mark Rubinstein, Chief Medical Officer, Achieve
“Most people need more than one attempt to quit, yet treatment beyond 12 weeks and retreatment had not previously been studied with cytisinicline”
Mark Rubinstein, Chief Medical Officer, Achieve
“These results provide the first data on extended treatment and retreatment with cytisinicline, and suggest that longer treatment of up to 52 weeks may help some people who smoke or vape sustain abstinence.”
Andrew D. Goldberg, Chief Executive Officer, Achieve
“This is the first year-long treatment trial we know of in people who were still smoking or vaping after a medically supported quit attempt, and the people in it look like the patients clinicians see every day: older, on other medications, and living with chronic conditions, many having also tried other treatments and still smoking”
Andrew D. Goldberg, Chief Executive Officer, Achieve
“Every one of them chose to try again, and nearly a third were not smoking or vaping at the end of a year.”
Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year
Among the participants new to cytisinicline (prior attempt on placebo), 39% had quit at the end of the year
Get started
Create a free account to read the full story.